Valor Compounding Pharmacy

Ultragenyx Pharmaceutical Inc, based in Novato, is at the forefront of rare disease medicine, dedicated to advancing the rare disease community. With a commitment to progress and innovation, Ultragenyx is shaping the future of healthcare for those with rare diseases. Driven by a mission to propel the rare disease field forward, Ultragenyx Pharmaceutical Inc is a leader in developing treatments and therapies for those in need. Their focus on rare diseases underscores their dedication to improving the lives of patients and caregivers worldwide. Generated from their website's infomation

Emery Pharma, located in Alameda, CA, is a leading analytical services company specializing in the development and characterization of molecules and products. Their state-of-the-art facilities and expert team offer a wide range of services, including bioanalytical, microbiology, and botanical drug development, catering to various stages of development and compliance requirements. With a focus on providing accurate and reliable solutions, Emery Pharma offers impurity analysis, biologics characterization, and litigation support, utilizing their extensive expertise and cutting-edge equipment. Their commitment to excellence and client satisfaction has made them a trusted partner in the pharmaceutical industry.Generated from the website

Exelixis is an integrated drug discovery and development company. The company utilizes cutting-edge genomic, molecular biology and combinatorial chemistry technologies to develop innovative therapies for significant human diseases. Its primary mission is to improve patient care by developing proprietary human therapeutics that target the complex molecular causes of disease. Exelixis has built a research and discovery platform. The Exelixis clinical development pipeline includes compounds in cancer and renal disease. The company s pre-clinical pipeline is comprised of six programs. The pre-clinical oncology programs consist of development candidates that focus on inhibiting kinases. In its pre-clinical metabolic disease programs, Exelixis has developed small molecules that modulate nuclear hormone receptors that implicate various metabolic and cardiovascular disorders. Corporate headquarters are in San Francisco. The research facility is in Portland, Ore.